Published: 6 January 2022
Author(s): Patricia Pardo-Martínez, Eduardo Barge-Caballero, Alberto Bouzas-Mosquera, Gonzalo Barge-Caballero, David Couto-Mallón, María J. Paniagua-Martín, Marta Sagastagoitia-Fornie, Óscar Prada-Delgado, Javier Muñiz, Luis Almenar-Bonet, José M. Vázquez-Rodríguez, María G. Crespo-Leiro
Issue: March 2022
Section: Original article

Mineralocorticoid receptor antagonists (MRA) play a central role in the therapeutic scheme recommended for patients with heart failure and reduced left ventricular ejection fraction (HFrEF). Three randomized clinical trials support the clinical benefit of MRA in these individuals; spironolactone was associated with increased survival as compared to placebo in patients with HFrEF and severe symptoms [1], while eplerenone showed improved outcomes in patients with HFrEF and mild symptoms [2], and also in patients with reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction and either symptomatic heart failure (HF) or diabetes mellitus [3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.